Company Capricor Therapeutics Inc Nasdaq
Equities
US14070B1017
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Transformative Cell and Exosome-based Therapeutics
100.0
%
| 3 | 100.0 % | 25 | 100.0 % | +886.81% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 3 | 100.0 % | 25 | 100.0 % | +886.81% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Karen Krasney
LAW | General Counsel | 71 | 11-12-31 |
General Counsel | 71 | 15-02-27 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
David Musket
BRD | Director/Board Member | 66 | 13-11-19 |
Frank Litvack
CHM | Chairman | 68 | 11-12-31 |
Karimah Es Sabar
BRD | Director/Board Member | 66 | 21-07-22 |
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Paul Auwaerter
BRD | Director/Board Member | 62 | 23-07-12 |
Michael Kelliher
BRD | Director/Board Member | 47 | 23-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 31,502,972 | 28,920,785 ( 91.80 %) | 0 | 91.80 % |
Company contact information
Capricor Therapeutics, Inc.
10865 Road to the Cure Suite 150
92121, San Diego
+858 727 1755
http://www.capricor.comSector
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |